Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticles

Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences

PROTON RAHMAN, ROBERT D. INMAN, HANI EL-GABALAWY and DENIS O. KRAUSE
The Journal of Rheumatology Supplement May 2010, 85 11-26; DOI: https://doi.org/10.3899/jrheum.091462
PROTON RAHMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: prahman@mun.ca
ROBERT D. INMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANI EL-GABALAWY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DENIS O. KRAUSE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Representation of the complex relationship between HLA susceptibility and psoriatic arthritis (PsA). Areas on the diagram are not to scale. The right side represents the presence of the Cw*0602 allele in healthy individuals, its strong association with psoriasis susceptibility, and the fact that about 40% of those with psoriasis lack Cw*0602. The left side illustrates the almost complete association of B*27 with ankylosing spondylitis. Both Cw*0602 and B*27 alleles contribute independently to PsA susceptibility. From FitzGerald O and Winchester R, Arthritis Res Ther 2009;11:21410; with permission from BioMed Central.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Proposed paradigm linking HLA-B27 misfolding to innate immune activation. HLA-B27 misfolding is hypothesized to result in activation of an intracellular stress response pathway known as the unfolded protein response (UPR), which leads to production of IL-23. Enhanced upregulation of interleukin 23 (IL-23) promotes IL-17 production from CD4 T cells of the Th17 lineage. Th17 cells can produce tumor necrosis factor-α (TNF-α) and IL-6, and IL-17 is also a potent proinflammatory cytokine that acts on many tissue cell types and further induces TNF-α, IL-6, and IL-1, as well as chemokines and metalloproteinases. From Colbert, et al, Prion 2009;3:15-2621; with permission from Landes Bioscience.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Model for T helper (Th) or T regulatory (Treg) differentiation from naive CD4+ T cells. T cell signaling requires formation of a contact [interface between an antigen-presenting cell (APC) and a T cell]. The key event in T cell stimulation is the activation of the T cell receptor (TCR) by antigenic peptides presented by MHC molecules on the APC. Other factors required for T cell differentiation and signaling include: activation of costimulatory molecules and costimulation by various cytokines via cytokine receptors. Th1 cells differentiate in the presence of IL-12, interferon-α/-ß/-γ, IL-18, and IL-27. Th2 cells depend on the presence of IL-4, IL-6, and IL-11. Th17 cells require a combination of transforming growth factor-ß1 and proinflammatory cytokines (such as IL-6). Upregulation of the IL-23 receptor makes these cells responsive to IL-23. Human Th17 cells produce IL-23, IL-21, and IL-17. From Zhernakova, et al, Nat Rev Genet 2009;10:43–554; with permission from Macmillan Publishers Ltd.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Contribution of known genetic risk factors for RA. HLA: human leukocyte antigen; PTPN2: protein tyrosine phosphatase, non-receptor type 2; STAT 3: signal transducer and activator of transcription 3; TRAF1/C5: tumor necrosis factor receptor-associated factor 1/complement component 5. From Bowes and Barton, Rheumatology 2008;47:399–40231; with permission of Oxford University Press.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Overview of normal NOD2-signaling pathway. Upon recognition of MDP, NOD2 recruits through homophilic interactions the adaptor RIP2. Once recruited, RIP2 activates NF-κB, p38, and ERK, which elicit immune response. NOD2-signaling has been shown to be essential for healthy conditions by modulating cytokines, chemokines, and defensin production. NOD2: nucleotide-binding oligomerization domain protein 2; Rip2: serine-threonine kinase (also known as RICK or CARDIAK); ERK: extracellular signal regulated kinases; MDP: muramyl dipeptide; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; Tak-1: transforming growth factor-ß-activated kinase 1. From Vignal, et al, Microbes Infect 2007;9:658–6343; with permission from Elsevier.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Overview of interleukin 12 (IL-12) and IL-23 ligand and receptor complexes. IL-23R: interleukin 23 receptor; IL-12Rß: interleukin 12 receptor beta; STAT: signal transducer and activator of transcription. From Boniface, et al, Immunol Rev 2008;226:132–4662; with permission from John Wiley and Sons Inc.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Development of anti-citrulline positive RA. From Klareskog, et al, Curr Opin Immunol 2006;18:650–585; with permission from Elsevier.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    A potential model comparing the normal ileum and the ileum in Crohn’s disease (CD). The presence of proinflammatory cytokines interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), as well as exposure to adherent invasive Escherichia coli, results in increased expression of CEACAM6 in the ileal epithelium of patients with CD. Increased CEACAM6 expression then mediates the adhesion of adherent invasive E. coli to the ileal epithelium. From Abraham and Cho, N Engl J Med 2007;357:708–1092. With permission from Massachusetts Medical Society. All rights reserved.

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9.

    RA tenosynovium is markedly hypoxic compared with non-RA synovium. Oxygen tension (mm Hg) measurements were carried out in invasive tenosynovium of 14 RA patients or in the synovium of 10 non-RA patients. Individual datapoints are means of 1–4 replicates from a given patient and were analyzed by Student’s unpaired t test, with bars showing median values. From Sivakumar, et al, J Hand Surg Am 2008;33:49–58125; with permission from Elsevier.

Tables

  • Figures
    • View popup
    Table 1.

    Strength of association between immune mediated-inflammatory diseases and HLA. From Zhernakova A, et al, Nat Rev Genet 2009; 10:43–554; adapted with permission from Macmillan Publishers Ltd.

    DiseaseAssociation* to HLA**PAR†
    Ankylosing spondylitisStrong0.43
    Crohn’s diseaseWeak0.03
    PsoriasisModerate-strong0.21
    Rheumatoid arthritisStrong0.5
    Ulcerative colitisWeak-moderate0.16
    • ↵* Only human leukocyte antigen (HLA) association in Caucasians has been reported.

    • ↵** HLA association: strong if the odds ratio for reported alleles is above 4; moderate if the odds ratio is between 2 and 4; and weak if the odds ratio is below 2.

    • ↵† Population attributable risk (PAR) was calculated based on the HLA single-nucleotide polymorphisms that showed the strongest association to the disease in genome-wide association studies.

    • View popup
    Table 2.

    Genes implicated in Crohn’s disease. Barrett JC, et al, Nat Genet 2008;40:955–6236; adapted with permission from Macmillan Publishers Ltd.

    Gene AssociationGene FunctionLocationPhenotype
    NOD2Peptidoglycan response16q12CD only
    IL-23IL-23 receptor1p31CD, UC + other IMID
    IL-12BInterleukin 12p405q33CD, UC
    ATG16LAutophagy gene2p37CD only
    PTPN2Tyrosine phosphatase18p11CD, UC + other IMID
    NKX2-3Gut immune development10q24CD, UC
    JAK2Transcription factor9p24CD
    STAT3Transcription factor17q21CD
    MHC regionMany6p21CD, UC + other IMID
    • NOD2: nucleotide-binding oligomerization domain protein 2; IL-23: interleukin 23; IL-12B: interleukin 12B; PTPN2: protein tyrosine phosphatase; non-receptor type 2; JAK2: Janus kinase 2; STAT 3: signal transducer and activator of transcription 3; MHC: major histocompatibility complex. UC: ulcerative colitis; IMID: immune-mediated inflammatory disease.

    • View popup
    Table 3.

    Effects of hypoxia on synovial cell cytokine release. Tenosynovial tissue was enzymatically dissociated and cells were cultured in either 1% oxygen (hypoxia) or 21% oxygen (normoxia) for a period of 24 hours. Cytokine and receptor release (ng/ml) into supernatants was measured by ELISA. Data are shown as median (interquartile range) and were analyzed by paired t test (for Gaussian distribution: IL-10, soluble VEGF-R1, VEGF) or Wilcoxon signed-rank test (for nonparametric data: IL-6, IL-8, MCP-1) versus normoxia. Sivakumar B, et al, J Hand Surg Am 2008;33:49–58125; with permission from Elsevier.

    VariableNormoxiaHypoxianp
    IL-68.64 (6.03–37.45)7.92 (5.06–38.46)120.677
    IL-83.11 (1.85–6.37)3.09 (1.92–7.61)120.622
    MCP-15.37 (2.06–31.80)2.25 (0.80–9.41)130.0002
    IL-102.86 (1.86–4.76)1.76 (0.86–2.99)120.001
    VEGF1.97 (0.79–3.92)4.86 (1.798–7.02)110.004
    Soluble VEGF-R10.16 (0.10–0.29)0.27 (0.15–0.43)140.001
    • IL-6: interleukin 6; MCP-1: monocyte chemoattractant protein-1; VEGH: vascular endothelial growth factor; VEGF-R1: vascular endothelial growth factor receptor 1.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology Supplement
Vol. 85
1 May 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences
PROTON RAHMAN, ROBERT D. INMAN, HANI EL-GABALAWY, DENIS O. KRAUSE
The Journal of Rheumatology Supplement May 2010, 85 11-26; DOI: 10.3899/jrheum.091462

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences
PROTON RAHMAN, ROBERT D. INMAN, HANI EL-GABALAWY, DENIS O. KRAUSE
The Journal of Rheumatology Supplement May 2010, 85 11-26; DOI: 10.3899/jrheum.091462
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • PATHOGENESIS OF IMID
    • ROLE OF MAJOR HISTOCOMPATIBILITY COMPLEX AND HLA
    • T CELL DIFFERENTIATION AND SIGNALING
    • GENES AND THE ENVIRONMENT IN DEVELOPMENT OF IMID
    • CONCLUSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • The Efficacy and Safety of Muscle Relaxants in Inflammatory Arthritis: A Cochrane Systematic Review
  • The Efficacy and Safety of Antidepressants in Inflammatory Arthritis: A Cochrane Systematic Review
  • Paracetamol for the Management of Pain in Inflammatory Arthritis: A Systematic Literature Review
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire